We are live on ! Find out more
BOLT icon

Bolt Biotherapeutics
BOLT

25 hedge funds and large institutions have $5.1M invested in Bolt Biotherapeutics in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 14 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.5% less ownership

Funds ownership: 47.8% → 46.3% (-1.5%)

14% less funds holding

Funds holding: 29 → 25 (-4)

30% less capital invested

Capital invested by funds: $7.33M → $5.1M (-$2.23M)

64% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 14

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

Holders
25
Holders Change
-4
Holders Change %
-13.79%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
14
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Squarepoint
Squarepoint
New York
+$54.2K
2
Morgan Stanley
Morgan Stanley
New York
+$19.8K
3
Renaissance Technologies
Renaissance Technologies
New York
+$17.3K
4
NA
NewEdge Advisors
Louisiana
+$3.2K
5
Bank of America
Bank of America
North Carolina
+$7

Top Sellers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
-$157K
2
UBS Group
UBS Group
Switzerland
-$35.7K
3
BlackRock
BlackRock
New York
-$19.1K
4
State Street
State Street
Massachusetts
-$19K
5
Northern Trust
Northern Trust
Illinois
-$16.4K

BOLT Hedge Fund Activity: Q2 2025 in Review

25 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q2 2025, worth a combined $5.1M — down 30% from $7.33M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of BOLT and 2 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 5 added.

The largest buyer was Squarepoint, adding an estimated $54.2K. The largest seller was Tang Capital Management, cutting an estimated $157K.

  • 25 institutional investors held Bolt Biotherapeutics (BOLT) as of Q2 2025, down from 29 in Q1 2025.
  • Funds reported $5.1M of Bolt Biotherapeutics stock for Q2 2025, down 30% quarter-over-quarter.
  • 2 funds opened new Bolt Biotherapeutics positions in Q2 2025 and 6 closed out, a net change of -4 holders.
  • The largest Bolt Biotherapeutics buyer in Q2 2025 was Squarepoint, an estimated $54.2K added.
  • The largest Bolt Biotherapeutics seller in Q2 2025 was Tang Capital Management, an estimated $157K sold.

Based on aggregated 13F filings for Q2 2025.